NICE issues draft guidance on setmelanotide for treating obesity caused by leptin receptor (LEPR) or proopiomelanocortin (POMC) deficiency
In DRAFT guidance, NICE is minded not to recommend setmelanotide as an option for treating obesity and controlling hunger caused by POMC deficiency, including proprotein convertase subtilisin/kexin type 1, or LEPR deficiency in people 6 years and over.
Source:
National Institute for Health and Care Excellence
SPS commentary:
The draft guidance notes that although the results from clinical trials suggest that setmelanotide may reduce weight and BMI in people with obesity caused by POMC and LEPR deficiencies, and improve hunger and quality of life, follow up in the trials is short, so the long-term effects of setmelanotide are uncertain. Also, it has not been compared with best supportive care, and there are a number of uncertainties in the economic modelling.